| |
Notes |
|
2018
R’000 |
|
| The following has been charged/(credited) in arriving at operating profit: |
|
|
|
|
|
|
| Fair value uplift |
|
|
(27 741) |
|
— |
|
| Contingent purchase price release |
|
|
(211) |
|
(1 390) |
|
| Fair value gain on financial instruments |
|
|
— |
|
(51 001) |
|
| Acquisition-related costs |
|
|
— |
|
6 041 |
|
| Advertising and promotional expenses |
|
|
24 509 |
|
27 426 |
|
| Audit fees – services as auditors |
|
|
29 770 |
|
22 018 |
|
| Audit fees – other |
|
|
1 436 |
|
2 816 |
|
| Consulting fees |
|
|
91 451 |
|
48 467 |
|
| Finance costs incurred in generating finance revenue |
|
|
177 100 |
|
71 656 |
|
| Foreign exchange (gain)/loss (refer to note 3.3) |
|
|
(36 621) |
|
19 648 |
|
| Impairment of inventory |
|
|
5 024 |
|
5 489 |
|
| IT infrastructure costs and computer-related costs |
|
|
48 722 |
|
34 497 |
|
| Legal fees |
|
|
12 579 |
|
923 |
|
| Profit on disposal of subsidiary |
|
|
— |
|
(2 824) |
|
| Motor vehicle expenses |
|
|
15 822 |
|
11 623 |
|
| Operating lease rentals – premises |
|
|
59 188 |
|
40 999 |
|
| (Profit)/loss on disposal of property, plant and equipment |
|
|
(761) |
|
(1 784) |
|
| Impairments and fair value losses comprise the following: |
|
|
|
|
|
|
| Arising from the application of IFRS 9 expected credit loss requirements: |
|
|
|
|
|
|
| Impairment of loans |
|
|
163 663 |
|
142 069 |
|
| Financial guarantee contracts |
3.6.3 |
|
58 832 |
|
— |
|
| Impairment of trade receivables – provision |
3.1 |
|
15 200 |
|
18 790 |
|
| Trade receivables written off |
|
|
6 115 |
|
7 443 |
|
| Other impairments and fair value movements: |
|
|
|
|
|
|
| Impairment of goodwill |
4.1 |
|
124 400 |
|
— |
|
| Surety receivable recognised |
3.5.1 |
|
(29 998) |
|
(55 005) |
|
| Fair value losses on financial instruments |
|
|
873 877* |
|
45 360 |
|
| |
|
|
1 212 089 |
|
158 657 |
|
| * This amount includes the fair value losses on SPV1, SPV2 and loans at fair value, net of VAT. Refer to note 3.7. |
|
|
|
|
|
|
| Impairments on associates and joint venture comprise the following: |
|
|
|
|
|
|
| Impairment of investment in OSI |
2.1 |
|
118 412 |
|
— |
|
| Impairment of investment in Cell C |
2.1 |
|
2 521 152 |
|
— |
|
| Impairment of investment in SupaPesa |
2.1 |
|
29 512 |
|
— |
|
| |
|
|
2 669 076 |
|
— |
|
| Included in impairments and fair value losses and impairments on associates and joint ventures above are the following: |
|
|
|
|
|
|
| Impairments and fair value losses relating to Oxigen |
|
|
|
|
|
|
| Impairment of 2DFine loan |
2.1 |
|
130 718 |
|
141 852 |
|
| Impairment of OSI loan |
2.1 |
|
30 511 |
|
— |
|
| Financial guarantee contracts |
3.6.3 |
|
62 132 |
|
— |
|
| Impairment of investment in OSI |
2.1 |
|
118 412 |
|
— |
|
| Surety receivable recognised |
3.5.1 |
|
(29 998) |
|
(55 005) |
|
| |
|
|
311 775 |
|
86 847 |
|
| Impairments and fair value losses relating to Cell C |
|
|
|
|
|
|
| Impairment of investment in Cell C |
2.1 |
|
2 521 152 |
|
— |
|
| Fair value loss on SPV1 and SPV2 |
3.7 |
|
750 263 |
|
45 360 |
|
| |
|
|
3 271 415 |
|
45 360 |
|